Metabolic Reprogramming of Monocytes in Inflammatory Flares of Inflammatory Bowel Diseases

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Hospital, Grenoble

About this trial

Inflammatory bowel diseases, Crohn's disease and haemorrhagic rectocolitis, are pathologies that progress in flare-ups, impacting on patients' quality of life and functional or even vital prognosis. These inflammatory diseases require the use of immunosuppressive and immunomodulatory treatments, the side-effects of which can be significant, and the limited number of which sometimes puts patients and practitioners in a therapeutic impasse from which surgery is the only way out. It is therefore important to be able to develop new therapeutic approaches, ideally better tolerated, that can control inflammation during relapses. Monocytes are one of the main players in the inflammatory reaction. In the laboratory, we have developed a strategy for the metabolic reprogramming of these cells based on the use of oxygen microbubbles to modulate the inflammatory response of monocytes.

Eligibility criteria

Qualifiers

Men and women over 18

Managed at the CHUGA for a severe IBD flare-up requiring hospitalisation or endoscopy for flare-up

Patient not objecting to the REPRO-MICI study

Disqualifiers

Patients protected by law (pregnant or breast-feeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalised under duress).

Patients with positive HIV, HBV or HCV serology.

Patients with a positive ELISPOT with no history of treatment for latent tuberculosis.

Trial design

Treatments tested in this trial

  • Blood test 4 EDTA tubes

Treatment groups

No treatment groups listed

Sponsors and collaborators

University Hospital, Grenoble

Lead sponsor

Institute for Advanced Biosciences (IAB), Grenoble

Collaborator